Has Brigatinib/Brigatinib been launched in China?

Brigatinib/Brigatinib (Brigatinib) is an oral anti-tumor drug used to treat specific types of non-small cells Lung cancer (NSCLC), especially ALK fusion-positive NSCLC.

Brigatinib/Brigatinib has been launched in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy. However, the price is quite high, more than 10,000 yuan. Foreign Brigatinib/Brigatinib are mainly generic drugs, mainly Bangladeshi and Laos generic drugs. The price of the international version of the Bangladeshi generic drug Yaopin is about 2000yuan, the specification is 90mg*30 tablets; the price of the Laos version of the generic drug is about 600, and the specification is smaller. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.

Brigatinib/The mechanism of action of Brigatinib is through inhibiting ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) The activity of these two proteins blocks the abnormal activation of cell signaling pathways and reduces the growth and spread of tumor cells. ALK and ROS1 are tyrosine kinases that are mutated or fused in some NSCLC patients, promoting tumor formation and progression. Brigatinib/The inhibitory effect of Brigatinib can block these abnormal signaling pathways and inhibit the proliferation of tumor cells.

AlthoughBrigatinib/BrigatinibIt is mainly used for the treatment of ALKfusion-positive NSCLC, but research shows that it is also effective for other types of NSCLChas certain anti-tumor activity, such as EGFRmutationsNSCLC. However, compared with traditional EGFR inhibitors, brigatinib has less therapeutic efficacy than traditional EGFR inhibitors. The efficacy is relatively low, so brigatinib is usually considered only when EGFR inhibitor treatment fails or becomes resistant.